Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026)

Arvinas (ARVN) recorded quarterly Liabilities and Shareholders Equity of $647.5 million in Q1 2026, down 9.81% quarter-over-quarter from $717.9 million in Q4 2025, and down 35.32% on a YoY basis from $1.0 billion in Q1 2025.

Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends

Arvinas' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $647.5 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity fell 35.32% year-over-year to $647.5 million; the TTM figure through Mar 2026 stood at $3.1 billion (down 31.29% YoY), while the FY2025 annual figure was $717.9 million, down 34.22% from the prior year.
  • Liabilities and Shareholders Equity was $647.5 million for Q1 2026 at Arvinas, down from $717.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q1 2022 to a low of $647.5 million in Q1 2026.
  • Historically, Liabilities and Shareholders Equity has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2024.
  • The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity jumped 118.47% in 2022, then sank 35.32% in 2026.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.3 billion in 2022, then gained by 2.82% to $1.3 billion in 2023, then dropped by 16.34% to $1.1 billion in 2024, then tumbled by 34.22% to $717.9 million in 2025, then decreased by 9.81% to $647.5 million in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $647.5 million (Q1 2026), $717.9 million (Q4 2025), and $844.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 37.37 Mn
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 811.27 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 14.93 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 1.73 Bn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 23.64 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 33.89 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 12.81 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 26.48 Bn
9 Abivax 91.96 Bn 91.96 Bn - 640.56 Mn
10 Arvinas 492.16 Mn -122.74 Mn - 647.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 647.50 Mn
Dec 31, 2025 717.90 Mn
Sep 30, 2025 844.30 Mn
Jun 30, 2025 909.30 Mn
Mar 31, 2025 1.00 Bn
Dec 31, 2024 1.09 Bn
Sep 30, 2024 1.17 Bn
Jun 30, 2024 1.28 Bn
Mar 31, 2024 1.21 Bn
Dec 31, 2023 1.30 Bn
Sep 30, 2023 1.06 Bn
Jun 30, 2023 1.08 Bn
Mar 31, 2023 1.18 Bn
Dec 31, 2022 1.27 Bn
Sep 30, 2022 1.33 Bn
Jun 30, 2022 1.41 Bn
Mar 31, 2022 1.49 Bn
Dec 31, 2021 1.58 Bn
Sep 30, 2021 1.60 Bn
Jun 30, 2021 644.03 Mn